Opinion|Videos|May 9, 2025
CHE: Symptoms and Diagnosis
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how chronic hand eczema (CHE) diagnosis relies on clinical features such as erythema, scaling, vesicles, hyperkeratosis, fissures, and erosions, which must be distinguished from atopic dermatitis through a comprehensive patient history and full-body examination.
Advertisement
Video content above is prompted by the following:
CHE Clinical Features and Diagnosis
Key Themes:
- Key clinical signs: Erythema, scaling, edema, vesicles, hyperkeratosis, fissures, and erosions, with more chronic than acute presentation.
- Differential diagnosis: Distinguishing CHE from atopic dermatitis requires a holistic history and full-body examination.
- Predominant symptoms: Beyond itching, skin pain represents a significant burden, particularly from fissures and cracking.
Notable Insights:
Dr Chovatiya emphasized that "from a patient perspective...a focus on skin pain as well as some of the cracking, bleeding, opening of skin, and wounding is going to be extraordinarily vital to really understanding the patient’s perspective."
Advertisement
Related to this article
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5